A5 Laboratories

A5 Laboratories has received approval letter for it’s containment level 2 facility.

gamry — Thu, 03 Feb 2011 19:50:09 +0000

MONTREAL, QUEBEC–(Marketwire – 02/03/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the office of Biohazard and Containment Safety in their letter dated February 1, received on February 2 stated the office has received and reviewed the inspection checklist for the animal Pathogen Containment Level 2 at our facility in Lachine and found them acceptable for work in vitro. We will be waiting for another approval from the authorities before being able to work in pathogen agent at our laboratories. This is pathogen like E.Coli, and some other bacteria will be needed to be used as standard in our CRO laboratories.

This is important news for us toward our capacity of performing tests and analysis in-house stated Richard Azani, president and CEO of A5 Laboratories.

More information about the Company is available at its corporate website at www.a5labs.com

About A5 Labs:

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5′s products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5′s expansion efforts, economic conditions in the industry and the financial strength of A5′s customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

A5 Laboratories, Inc. Announces Successful Production of VI-1718 Interferon Product

gamry — Tue, 01 Feb 2011 15:05:37 +0000

MONTREAL, QUEBEC–(Marketwire – 02/01/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the successful production of its VI-1718 interferon product by its European manufacturing partner. The European partner was successful in producing 2,000 doses of VI-1718 based on A5 Labs proprietary novel production technology. The company was further informed that the VI-1718 samples passed all quality control and anti-viral tests conducted by the European partner.

A5 Labs will receive the 2,000 doses in the next 3 to 4 weeks, at which time the company will conduct its own as well as independent lab tests for potency and efficacy.

“I am extremely pleased with the production of VI-1718 samples and the test results obtained by our European manufacturing partners. We have thus far shown that our technology is capable of producing small scale potent interferon products. In the next 3 to 4 weeks will release the complete results of the potency and efficacy of the VI-1718. ” said Dr. Richard Azani, President and CEO.

More information about the Company is available at its corporate website at www.a5labs.com

About A5 Labs:

Safe Harbor Statement:

Contact:

Investor Relations Contact

Andrew Barwicki

516-662-9461

andrew@barwicki.com

A5 Laboratories Inc Provides Operational Update

gamry — Wed, 19 Jan 2011 15:20:22 +0000

MONTREAL, QUEBEC, Jan 19, 2011 (MARKETWIRE via COMTEX) — A5 Laboratories Inc. (OTCBB: AFLB) is pleased to announce successful completion of laboratory scale manufacturing of porcine interferon.

Richard Azani, Chief Executive Officer of A5 Laboratories Inc., stated: “We view the manufacturing of porcine interferon as a major milestone in our business plan and we are now prepared to enter the next phase. The porcine interferon has been produced according to our proprietary technology.”

“Successful manufacturing of porcine interferon is the first step toward manufacturing of interferon for the veterinary field. The same production technology applied to other cell lines would allow us to obtain interferon for given species, including but not limited to bovine, equine, poultry, among many more. Our next target would be bovine interferon, continued Mr. Azani.

About A5 Laboratories Inc

A5 Laboratories is a specialty biotechnology company engaged in the development and marketing of novel immun therapeutic applications of a natural Gamma – Interferon (nG-IFN). Such applications include the diagnostic, the prevention and the treatment of various animal and human diseases.

The pathologies targeted by Cytokines Biotech’s nG-INF include viral, bacterial, fungal and parasitic infections as well as various auto-immune conditions and cancer, and emphasis will be initially put on opportunistic infections in HIV patients, antibiotic-resistant bacteria and some rare types of cancers.

SAFE HARBOR STATEMENT

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to A5, and specifically the production and testing of A5′s interferon product, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5′s products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5′s expansion efforts, economic conditions in the industry and the financial strength of A5′s customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contacts:
Investor Relations Contact
Andrew Barwicki
516-662-9461
andrew@barwicki.com

SOURCE: A5 Laboratories Inc.

CONTACT: mailto:andrew@barwicki.com

Copyright 2011  Marketwire, Inc., All rights reserved.

SUBJECT CODE: Pharmaceuticals and Biotech:Biotech

A5 Laboratories Inc. Retains Barwicki Investor Relations

gamry — Wed, 29 Dec 2010 20:13:38 +0000

Lachine, Quebec, Dec 22, 2010 (Newsfile Corp via COMTEX) — A5 Laboratories Inc. (OTC:BB AFLB) is pleased to announce that it has retained Barwicki Investor Relations Inc. to initiate a strategic investor relations program that will provide information to institutional and individual investors.

Richard Azani, Chief Executive Officer of A5 Laboratories Inc., stated: “”As we continue to grow our operations, we believe this is the right time to send our message to the investment community. After careful consideration, Barwicki Investor Relations Inc., with their established relationships among institutional investors, combined with their extensive databases and pro active investor relations program, is the perfect partner for A5.”

Barwicki Investor Relations Co. is run by Andrew Barwicki, a seasoned veteran with 19 years of marketing and investor relations experience. Barwicki Investor Relations has a database of 73,000 money, fund & portfolio managers, 92,000 stock brokers and 54,000 individual investors.

Barwicki Investor Relations will provide the investment community with information and updates about A5 Laboratories Inc., schedule road shows, conference calls and one-on-one meetings with institutional investors and broker dealers throughout the United States. The investor relations program will also target retail investors and bio tech investors specifically.

About A5 Laboratories Inc

SAFE HARBOR STATEMENT

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to A5, and specifically the production and testing of A5′s interferon product, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5′s products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5′s expansion efforts, economic conditions in the industry and the financial strength of A5′s customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

A5 Laboratories Inc. Announces Preparation of Initial VI-1718 Interferon Product

gamry — Thu, 02 Dec 2010 16:00:09 +0000

MONTREAL, QUEBEC–(Marketwire – 12/02/10) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB - News) announced today that its European partner has begun the preparation and production of the VI-1718 interferon product. Using A5 Labs production technology, it is anticipated that approximately 2,000 doses of the VI-1718 will be manufactured with certificates of analysis in the next 4 weeks. A5 Labs expects that it will begin a multi-center production and in-vitro test of the interferon product to establish proof of concept potency in the next 6 to 8 weeks.

“I am extremely pleased to report to our shareholders the start of the production of VI-1718. In the next 6 to 8 weeks we plan further production and testing the product for its potency and efficacy in independent labs, the results of which will be a significant milestone towards initiation of submission for animal and human clinical trials,” said Dr. Richard Azani, President and CEO.

About A5 Labs:

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5′s products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5′s expansion efforts, economic conditions in the industry and the financial strength of A5′s customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

A5 Laboratories Inc. Completes Validation of Its CRO Laboratory Information Management System (LIMS)

gamry — Wed, 10 Nov 2010 17:58:19 +0000

MONTREAL, QUEBEC–(Marketwire – 11/09/10) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) is pleased to announce that the CRO division has completed the validation of its proprietary Laboratory Information Management System (LIMS). The unique custom-made LIMS system will allow A5 Labs’ CRO customers to track and receive real-time information on the progress and status of the analysis of their products. The customers will use the Web-based LIMS system to submit requisitions and track the results of the analysis at each stage of the testing as well as purchase copy of the raw data.

“The validation of our LIMS system is a critical step in the start of pharmaceutical CRO business. We anticipate that the LIMS system will significantly increase the productivity of our CRO and will deliver total Quality Assurance to our customers on a timely manner.” Said Dr. Richard Azani, President and CEO.

A5 Laboratories Inc. Expands Management for the Development of Interferon Projects

gamry — Mon, 08 Nov 2010 18:00:14 +0000

MONTREAL, QUEBEC–(Marketwire – 11/02/10) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) today announced the appointment of Dr. Abderrazzak Merzouki to the position of Director of Cell Engineering and Biotherapeutics. Dr. Merzouki is molecular biologist and immunologist with extensive experience in the advancement of biological molecules, such as interferons, through their preclinical and clinical phases of analysis and development. He has previously been a consultant in the development of products for Introgen Therapeutics Inc., Gencell (Japan), Aventis Pharma, Genomics One, ID Biomedical, Shire and Rhone Poulenc Rorer. In his role at A5 Labs, Dr. Merzouki will direct all aspects of interferon product development as well as strengthening and enhancement of the company’s patent portfolio.
Dr. Merzouki obtained his M.Sc. and Ph.D. in immunology from Armand-Frappier Institute in Quebec in 1996 and received his post-doctoral training at the University of British Columbia and BC Center for Excellence in HIV/AIDS research. From 1999 until 2007 he was professor of Immunology at the Armand-Frappier institute. In 2007, Dr. Merzouki joined the Institute of Biomedical Engineering at the Ecole Polytechnique de Montreal as a senior scientist where he has directly been involved in the latest research and development of interferon based therapies. Dr. Merzouki has over 25 publications in the most respected journals in the field of cellular and molecular biology.

“I am very pleased to welcome Dr. Merzouki to our interferon development team. His extensive knowledge of the latest developments in interferon therapies will provide a significant depth to our management and will put A5 Labs at the forefront of interferon product development,” said Dr. Richard Azani, President and CEO.

A5 Laboratories Inc. Signs Partnership Agreement for the Production of Interferon Products

gamry — Thu, 28 Oct 2010 16:42:38 +0000

MONTREAL, QUEBEC–(Marketwire – 10/26/10) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) today announced the signing of a binding agreement with a European-based Institute of Microbiology for the production of interferon products. The Institute has agreed to manufacture natural source interferon products using A5 Labs’ proprietary production technology. The production of interferon finished products at the Institute will represent an important step in validation of A5 Labs’ production technology. Subsequently, A5 Labs plans to submit the products manufactured at the institute for in-vitro and in-vivo testing according to USP (United States Pharmacopaeia) guidelines at multi-centered independent laboratories.

The agreement was drafted following the meetings between the respective managements of A5 Labs and the Institute during the last week of September 2010.

“We are extremely pleased to sign this partnership agreement with such a prestigious Institute. This is a highly significant milestone which will provide a leap forward towards the commercialization of our natural source interferon products. Following the laboratory and scale up production of our products we will immediately begin our veterinary trials and submission of our application for human clinical trials,” said Dr. Richard Azani, President and CEO.

A5 Laboratories Inc. Announces Additional CRO Customers

gamry — Wed, 29 Sep 2010 16:20:36 +0000

MONTREAL, QUEBEC–(Marketwire – 09/29/10) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today that its CRO division has successfully added several additional customers for its environmental assessment business unit. A5 Labs will provide these customers a variety of phase 1, 2 and 3 environmental assessment testing and reporting services including testing of industrial water, soil and atmospheric emissions. Specifically, A5 Labs will provide the following services:

– Industrial water testing for Avior Integrated Products (supplier of
lightweight structural assemblies for international aerospace industry),
F.D. Jul (manufacturer of shelving systems and mobile storage units) and
Bel products (manufacturer of electronic enclosures)
– Product contamination assessment for Vulcain, a division of Honeywell, a
manufacturer of environmental detection systems
– Phase 1, 2 and 3 water and soil contamination testing for Bank of
Montreal and National Bank of Canada. A5 Labs will conduct these tests
for properties under financing consideration by these banks.
– Phase 1 environmental assessment for Century 21 (real estate company) in
Quebec
– Atmospheric emissions testing and assessment for Le Plastique Balcan and
Multisac packaging (leading manufacturers of flexible packaging and
lamination films).

“I am very pleased with the progress of our CRO group and the environmental assessment unit. Addition of these customers will greatly increase our visibility and penetration in the environmental assessment market. We plan to build on this momentum and significantly increase our sales for the coming fiscal year.” said Dr. Richard Azani, President and CEO.

A5 Laboratories Inc. Engages Mirador Consulting for Financial Advisory and Public Relations Representation

gamry — Fri, 24 Sep 2010 16:31:20 +0000

MONTREAL, QUEBEC–(Marketwire – 09/22/10) – A5 Laboratories Inc. (OTC.BB:AFLB – News) announced today that is has entered into an agreement with Mirador Consulting (www.miradorconsulting.com), a Florida based corporate consulting firm, to provide A5 Laboratories Inc. financial advisory and public relations representation in an effort to proactively and accurately present the Company to the public and investment community in a compliant, clear, and effective manner.

The agreement provides A5 Laboratories Inc. with professional representation in the public marketplace while allowing A5 to focus on its day to day business, revenue growth, and increasing shareholder value as it continues to execute on its accelerated production and acquisition strategy. Mirador’s services provide hands-on proactive and critical solutions for A5 Laboratories Inc. financial advisory and public relations needs.